Analyzing specific KRAS variants and treatment outcomes in colorectal cancer

RWD analysis reveals distinct survival outcomes based on specific KRAS variants in CRC

INDICATION
Colorectal
BIOMARKER
KRAS

 

Kaplan-Meier survival curves comparing rwOS for KRAS variant in pre-treatment samples from CRC patients anchored on 1L anti-VEGF/anti-EGFR treatment. Median survival times (months) are specified. Log-Rank test P value is indicated.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

2026-07-01
Pancreatic
KRAS
BRCA2
SMAD4
CDKN2A
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A grid of small colored squares forms abstract patterns and diagonal flows.

Prognostic impact of GLP-1RA treatment in colorectal cancer patients with type 2 diabetes or obesity

2026-07-01
Colorectal
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Survival curve illustrating two distinct groups, blue and black, with varying outcomes over time.

ATM expression as a predictive biomarker for first-line treatment outcomes in metastatic CRC

2026-05-26
Colorectal
ATM